Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Carcinoma

Laryngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Laryngeal Diseases

Respiratory Tract Diseases

Respiratory Tract Neoplasms

Otorhinolaryngologic Diseases

Laryngeal Cancer

Patients undergoing endoscopic treatment with CO2 laser

Patients undergoing endoscopic treatment with KTP laser

surgical removal of carcinoma from the vocal cords with CO2 laser

CO2 laser

surgical removal of carcinoma from the vocal cords with KTP laser

KTP laser

Yonatan Lahav, Dr

Yaara Haimovich

comparison results of treatment of early stage glottic cancer between two methods of surgical treatment - CO2 laser and KTP laser

Randomized controlled double-blinded study. The study group includes patients diagnosed with early glottic cancer, either carcinoma in situ or T1a-b,N0M0 squamous cell carcinoma.

Patients will undergo examination and treatment and at least 3 years of follow-up.

40 cancer patients will be included. The participants will be randomly divided into two groups: the first will be treated by KTP laser and the second by CO2 laser.

The patients will be blinded to the method of treatment. To enable double-blinding, the investigator performing the surgery would be the only one knowing which research group the patient belongs to. The investigator in charge of collecting the data after the operation will be blinded to the treatment method.

Each participant will undergo pre-operative evaluation and follow-up after surgery in both arms.

Preoperative evaluation will include:

* Voice Handicap Index questionnaire
* GRBAS - subjective assessment of voice quality.
* Video-stroboscopy of vocal cords
* Voice Analysis .

Follow-up after surgery:

* Visit 6 weeks after surgery (± two weeks), and then every three months (± 6 weeks).
* repeated full evaluation (questionnaire, GRBAS, Stroboscopy, voice analysis) in 30 weeks of follow up and 3 years of follow up.

KTP vs CO2 Laser for the Treatment of Laryngeal Carcinoma

Comparison Between the Use of KTP Laser vs. CO2 Laser for Endoscopic Surgical Removal of Malignant Neoplasms of the Vocal Cords

total time (minutes) of surgical procedure

total number of surgical interventions needed to eliminate the disease

recovery in terms of overall function, breathing, swallowing and vocal communication

objective measurement- voice lab analysis, and subjective measurement- Voice Handicap Index questionnaire

evidence of malignant disease in the larynx, cervical lymph nodes or distant metastases

Kaplan Medical Center

Dr Yonatan Lahav

Infections

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Condylomata Acuminata

Warts

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Genital Diseases

Urogenital Diseases

Skin Diseases, Infectious

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Interferons

Participants receive CO2 laser treatment followed by local injection of 36mcg of Peginterferon α-2b directly into the base of each treated wart, repeated weekly for 12 weeks, and then followed for another 12 weeks.

Peginterferon α-2b injection

Participants undergo CO2 laser treatment and then receive a weekly subcutaneous injection of 180mcg of Peginterferon α-2b for 12 weeks, and then followed for another 12 weeks.

On the day (baseline), CO2 laser treatment was performed to remove all warts, and the treatment range was 0.2cm around the lesion and the depth was up to the dermis. Wound disinfection after laser. Participants are treated with CO2 laser therapy only and are observed for 12 weeks, followed by another 12-week observation period without any additional adjuvant therapy.

Zhangyu Bu

Kune Lu

This is a prospective, randomized, open-label, controlled study, aiming to enroll 30 patients with Condylomata Acuminata. The study consists of two phases: a treatment phase (Weeks W1-W12) and an observation phase (Weeks W13-W24). Eligible patients will be randomly allocated into three groups at a ratio of 1:1:1: Test Group 1, Test Group 2, or the Control Group. And clinical cure, recurrence rates, adverse events, vital signs, laboratory tests, drug exposure doses, premature withdrawals will be analyzed.

Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata

A Prospective, Exploratory Study to Evaluate the Efficacy of Peginterferon α-2b Injection Combined With Carbon Dioxide(CO2) Laser in the Treatment of Condylomata Acuminata

Attending Physician

Syndrome

Breast Neoplasms

Breast Diseases

Menopause

Aromatase Inhibitors

Group A: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to zero potence.

Group B: Arm using basal treatment and adding vaginal laser using double blind to adjust the treatment to regular potence.

CO2 LASER

CO2 SHAM LASER

Immaculada Alonso Vargas

Background: Vulvovaginal health, directly linked to sexual health, is a key factor for female pleasure. BCS receiving AI are likely to present severe GSM and sexual complaints. Innovative options, as vaginal laser therapy, are emerging to treat GSM and sexual dysfunctions. Nowadays, data in BCS is scarce, moreover, few studies included patients receiving AI \[16\]. Different meta-analysis \[17-23\] found GSM \[24, 25\] and sexual function \[9, 10\] may improve significantly at short-term, however, the body of evidence is of low quality. Therefore, before recommendation of laser therapy for sexual complaints in BCS with GSM, there are unmet needs to be solved: efficacy and safety at long-term, biases related to patients' expectations and a detailed assessment of the complex underpinnings of sexuality.

Aims: To evaluate sexual and vaginal health in BCS receiving AI with GSM, before and after CO2 laser therapy compared to a sham-controlled group.

Methods: Prospective, randomized, double-blind controlled study with two parallel study arms: 1) Fractional CO2 laser therapy (5monthly sessions). 2) Sham laser therapy (5monthly sessions). After end-treatment, patients are followed up at 1 month and 6 months. BCS treated or undergoing AI with GSM and sexual function impairment, will be suitable. All patients will maintain first-line non-hormonal treatment and sexual assessment (PLISSIT Model) according with usual care. The primary outcome is improvement in sexual function (FSFI total score). As secondary outcomes: resumption sexual activity, sexual activity frequency, dyspareunia (VAS), female sexual dysfunction, sexual dimensions (FSFI), body image (S-BIS), quality of life (SF-12), vaginal pH acidification, maturation index and Vaginal Health Index of Gloria Backmann, adverse events, satisfaction (Likert scale) and adherence to treatment.

Expected impact: Emergent, non-invasive, laser therapy has significant benefit for BCS with AI, improving subjective and objective sexual and vaginal health outcomes and adding value to the usual care multidisciplinary approach.

BACKGROUND:

Sexuality is a central aspect of being human throughout life encompasses sex, gender identities and roles, sexual orientation, eroticism, pleasure, intimacy and reproduction. Most of these aspects may be affected in breast cancer survivors (BCS). In a recent meta-analysis, focused on sexual function through Female Sexual Function Index (FSFI) among BCS, female sexual dysfunction prevalence was 73,4% (95 % CI 64-82.8 %, I2 = 96.8 %) and mean FSFI 19.28 (95 % CI 17.39-21.16, I2 = 97.6 %). Several modifiable risk factors for sexual dysfunction in BCS may be optimum targets for intervention: amelioration of vaginal discomfort and urinary incontinence, the benefits of breast conserving surgery on body image or the evaluation of relationship quality. Due to the multifaceted nature of the factors affecting sexuality in BCS, most authors encouraged the need for comprehensive assessment and for a multidisciplinary approach.

BC diagnosis and/or its treatments (surgery, chemoradiotherapy, hormonal therapy) may altered sexual health. Vulvovaginal health, directly linked to sexual health, is a key factor for female pleasure. Genitourinary syndrome of menopause (GSM) is caused by decline in estrogen at menopause, which may also appear or worsen after systemic cancer treatments as aromatase inhibitors (AI). GSM is associated with sexual symptoms (lack of lubrication, discomfort or pain, impaired function), genital symptoms (dryness, burning, irritation) and urinary symptoms (urgency, dysuria, recurrent urinary tract infections). BCS receiving AI are one of the groups most likely to present severe GSM and sexual complaints. A cross-sectional study on 129 BCS during the first 2 years of adjuvant AI therapy, found 3 out of 4 women were distressed about their sexual problems. Only 52% of women had been sexually active when endocrine therapy began, but 79% of that group developed new sexual problems.

The first line of treatment for GSM is non-hormonal therapy (regular sexual activity, moisturizers-lubricants, pelvic-floor relaxation techniques, dilators) although in many women these options will not adequately control symptoms. Hormonal therapies must be used with caution in women with estrogen-dependent cancers. So, alternative options are emerging for this subset of patients, such as vaginal laser therapy. Different studies provided short-term data on non-cancer patients that showed laser therapy was feasible, safe and improved objective and subjective GSM. Data regarding sexuality derived from secondary endpoints and suggested that laser therapy may improve sexual function, mainly decreasing sexual pain. To date, data on laser therapy in BCS is scarce, moreover, few studies included patients receiving ongoing AI. The CO2 laser was the most frequently used device. Different reviews and meta-analysis found GSM and sexual function may improve significantly at short-term, however, the body of evidence is of low quality. Therefore, before recommendation for the use of laser therapy for sexual complaints in BCS with GSM, there are unmet needs to be solved as efficacy and safety at long-term, biases related to patients' expectations of therapy and a detailed assessment of the complex underpinnings of sexuality.

AIMS:

To answer the unmet needs previously mentioned, the aim of the current study is to verify the outcomes of sexual and vaginal health in breast cancer women receiving AI, who were experiencing symptoms of GSM, before and after CO2 laser therapy compared to a sham-controlled group.

Specifically, we will compare the following subjective and objective measurements of sexual and vaginal health:

MAIN GOAL: Report an improvement in sexuality:

* Primary outcome: sexual function (FSFI total score)
* Secondary sexual outcomes: resumption sexual activity (sexually active vs non-sexually active), sexual activity frequency (nº sexual activity/week), dyspareunia (VAS), female sexual dysfunction (VAS sexual life distress), sexual dimensions: desire, arousal, lubrication, orgasm, satisfaction and pain (FSFI) and body image (S-BIS)

OTHER OBJECTIVES: Report an improvement on GSM symptoms (efficacy) and quality of life, feasibility and safety of laser therapy in BCS:

- Secondary non-sexual outcomes: quality of life (SF-12). Verify an acidification of the vaginal pH, an improvement in the maturation index and an improvement in the Gloria Backmann Index: Vaginal Health Index. To evaluate toxicity associated with vaginal laser therapy in this population (AEs and SAEs). To determine how many women with the defined patient eligibility will complete all treatments.

METHODS:

DESIGN: Prospective, randomized, double-blind controlled study with two parallel study arms: ARM I: Patients undergo fractional CO2 laser therapy at 5 times points 30 days apart. ARM II: Patients undergo sham laser therapy at 5 time points 30 days apart. After completion of the treatment, patients are followed up at 1 month and 6 months.

RANDOMIZATION PROCESS: A randomization list will be generated in multiple blocks of 2 and 1: 1 ratio with STATA version 15.1 or higher.

STUDY SUBJECTS: Patients treated or undergoing AI for BC in the Breast Cancer Unit of the Hospital Clínic and who present symptoms related to GSM that condition their sexual function and quality of life, despite receiving first-line non-hormonal treatment: regular sexual activity (such as mutual and self-touch masturbation, manual or vibrator stimulation, oral sex, sexual intercourse, massage and other forms of physical intimacy), moisturizers, lubricants, pelvic-floor relaxation techniques and/or dilators. Inclusion and exclusion criteria are summarized in Table 1.

STUDY GROUPS: All patients will receive instructions to maintain first-line non-hormonal treatment, as well as sexual assessment using the PLISSIT Model according with usual care in our hospital.

The study group will be treated with a vaginal fractionated CO2 laser protocol (The SMARTXIDE TOUCH (Deka) equipment with an autoclavable vaginal probe following the manufacturer's protocol.

The control group will receive treatment with a sham-CO2 laser using a double-blinded protocol.

STUDY STRUCTURE.

SAMPLE CALCULATION Considering FSFI score as the main variable of the study, a sample size of 22 subjects for each group was calculated, accepting an alpha risk=0.05 and a beta risk \<0.1 in a bilateral contrast. The common standard deviation was considered to be of 8 points and the minimum expected effect size of 6 points. Considering follow-up loss rate of 15%, the sample size should be 51 patients.

STATISTIC ANALYSIS Descriptive statistics will be used according to standard calculation methods. The comparison between the two treatments at the end of the study will be evaluated through the change with the baseline using a mixed repeated measures model (MMRM) adjusted for the baseline value and including the treatment and the time in the model.

The variables of repetitive evaluation over time are analyzed according to the following strategy: (a) continuous variables with a repeated measures mixed longitudinal model (MMRM); (b) binary or non-normal variables with marginal models (Generalized Estimating Equation: GEE). Other variables will be studied as follows: Fisher's exact test for categorical variables, Student's t test for continuous variables between 2 groups. Non-parametric methods for independent data (Mann-Whitney U for 2 groups or Kruskall-Wallis test for more than 2 groups) will be used if necessary. The level of statistical significance will be 5% bilateral. The main analysis will be by Intention to Treat (ITT).

IMPACT:

What would be the impact of the project on sexual medicine field when it is successfully completed? Please explain how your project fits to the specific call

The BCS receiving AI are at higher risk of developing GSM symptoms. Sexual issues are common, either secondary to painful sex or as a direct effect of estrogen deprivation in the brain. However, addressing sexual health issues in BCS still meets several barriers from both, patient and health care professionals. GSM symptoms do not put survival at risk, however, have a significant impact in the quality of life.

The first-line treatment for GSM symptoms should be non-hormonal therapies according clinical guidelines, although frequently it will be insufficient to alleviate symptoms. Hormonal therapies are not currently recommended and must be used with caution in BCS. So, energy-based treatments have emerged as a promising option in this subgroup of patients. However, the body of evidence is lacking to make decisive recommendations \[18\], specially to treat sexual complaints. There is an urgent need to carry out RCT with larger sample size, long-term follow-up and blinded control group for answer various unmet needs in this field: short/mid and long-term safety issues and efficacy, treatment modalities (type of laser) and protocols (laser parameters, sessions numbers, repetitions).

This project aims to demonstrate that emergent, non-invasive, non-anesthetic laser therapy has significant benefit for BCS with AI, measured in a prospective, randomized, double-blind controlled trial using validated tools for subjective and objective sexual and vaginal health outcomes and quality of life.

Moreover, sexual health is a state of physical, emotional, mental and social well-being in relation to sexuality which requires the possibility of having pleasurable and safe sexual experiences. So, both arms of study groups will benefit from multidisciplinary approach including non-hormonal therapies (regular sexual activity, moisturizers, lubricants, pelvic floor relaxation techniques and/or dilators) and sexual assessment using the PLISSIT Model according with usual care in our hospital and with international recommendations.

randomized, double-blind, sham-controlled trial

Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy

Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy: A Randomized, Double-blind, Sham-controlled Trial - LIGHT Study

The 19 items of the FSFI use a 5-point Likert scale ranging from 1-5 with higher scores indicating greater levels of sexual functioning on the respective item. To score the measure, the sum of each domain score is first multiplied by a domain factor ratio (0.6 for desire; 0.3 for arousal; 0.3 for lubrication; 0.4 for orgasm; 0.4 for satisfaction; and 0.4 for pain) in order to place all domain totals on a more comparable scale, and then subsequently summed to derive a total FSFI score.

Measured by Vaginal ultrasound/vaginal biopsy.

Visual Analogue Scale of sexual life distress

Hospital Clinic of Barcelona

Principal Investigator, Clinical Professor

Skin Neoplasms

Cicatrix

Group 1 will receive laser therapy to half of the scar the day of the excision.

Group 2 will receive laser therapy at the time of suture removal or post-operative day 14.

Group 3 will receive laser treatment to half the scar at the 9 week postop visit.

The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.

Laser Treatment

Hooman Khorasani, MD

The purpose of this study is to evaluate the potential benefits of treating a surgical scar post excision with an ablative fractionated CO2 laser with the goal of decreasing the appearance and size of the scar.

The objective of this research is to determine, through a split scar study, that treating a post excision scar with a fractionated ablative CO2 laser improves both the texture and cosmetic appearance of the scar. An attempt will be made to determine the ideal timing for treating the excision scar as previous studies have ranged from treating the day of the excision up till 10 weeks post-excision. In order to evaluate the treated portion versus untreated portion of the scar, investigators and the subjects will use a quartile rating scale. In addition, punch biopsy samples will be taken to quantify the difference in collagen architecture 9 weeks after treatment with the laser.

There will be a total of 7 study visits to include the day of the excision and laser treatment if randomized to this group, post-op day number 14 for suture removal as well as laser therapy if the subject has been randomized to that treatment group, 4 weeks post-op, 9 weeks post-op and laser treatment for subjects randomized to this time frame for treatment, 12 weeks post-op, 17 weeks post-op and 24 weeks post-op. Each visit will last approximately 30-45 minutes each in which clinical photos of the surgical scar will be taken and any wound care or side effects of the laser therapy or surgery will be addressed. Healing and scar appearance will be reviewed and rated at each of the six postsurgical visits.

Post Excision/Mohs Scar Laser Resurfacing

Post Excision/Mohs Fractional CO2 Resurfacing: A Quantitative and Qualitative Scar Analysis Study

modified Manchester scar scale (MMSS) treated - Full scale from 5 to 18, with higher score indicating lower health outcomes

Fd indicates scar tissue density - a measure of how completely an object fills space and increases in value with increasing structural density. It has a value between 1 and 2: a minimum value of 1 corresponds to a straight line filling the space, and a maximum value of 2 corresponds to an object completely occupying the entire space.

Lacunarity describes the characteristics of fractals of the same dimension with different texture appearances and indicates scar tissue architecture (homogeneous vs. heterogeneous) - a measure of the nonuniformity (heterogeneity) of a structure or the degree of structural variance within an object. L has a value between 0 and 1, where a minimum value of 0 corresponds to an absolute homogeneous object.

Comparison of scars using quartile scale: 0 indicates no difference, 1 indicates a 1-25% difference or "mild" difference, 2 indicates a 26-50% or moderate difference, 3 indicates a 51-75% or significant improvement and 4 indicates a 76-100% difference or very significant.

Icahn School of Medicine at Mount Sinai

Clinical Professor

Participants with wounds to limbs of Fitzpatrick skin phototype I or II to receive laser therapy to half of the scar the day of the excision, Day 0; and to the other half on Day 14.

Participants With Fitzpatrick Skin Phototype I or II

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

Scar length

Single-center study with wounds limited to limbs of skin phototype I-II subjects.

Dr. Hooman Khorasani

Day 0

Day 14

MMSS for Scar Halves Treated

Fractal dimension (Fd) Day 0

Fractal dimension (Fd) Day 14

Lacunarity Day 0

Lacunarity Day 14

Quantitative Scar Analysis as Measured by Fractal Dimension (Fd) and Lacunarity

Quartile Scale

Overall Study

Carcinoma, Basal Cell

Bowen's Disease

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Basal Cell

Carcinoma, Squamous Cell

Neoplasms, Squamous Cell

Anti-Arrhythmia Agents

Channel Blockers

Central Nervous System Depressants

Vasoconstrictor Agents

Respiratory System Agents

Dermatologic Agents

Lidocaine

Anesthetics

Epinephrine

Anesthetics, Local

Aminolevulinic Acid

Racepinephrine

Epinephryl borate

Methyl 5-aminolevulinate

Sodium Channel Blockers

Diuretics, Potassium Sparing

Adrenergic Agents

Adrenergic alpha-Agonists

Adrenergic Agonists

Neurotransmitter Agents

Adrenergic beta-Agonists

Bronchodilator Agents

Anti-Asthmatic Agents

Mydriatics

Sympathomimetics

Photosensitizing Agents

The treatment starts with a full ablative CO2 laser pretreatment under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with a LED lamp. This treatment is repeated after 14 days.

The treatment starts with a fractional ablative CO2 laser ablation under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with LED lamp. This treatment is repeated after 14 days.

ablation to the level of de dermal papilla

full ablative CO2 laser

180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)

fractional ablative CO2 laser

LED lamp

lidocaine hydrochloride 2% with epinephrine

Barbara Boone, MD PhD

Photodynamic therapy (PDT) is a well established treatment option for superficial non melanoma skin cancer, such as superficial basal cell carcinoma (sBCC) and Bowen Disease (BD). However, a limited uptake of the topically applied photosensitizer methyl aminolevulinate (MAL) may reduce its efficacy. Pretreatment with an ablative carbon dioxide (CO2) laser has recently been studied in order to enhance the skin penetration of this photosensitizer. This study compares the results of a full ablative and a fractional ablative CO2 laser mode as pretreatment of PDT in the management of sBCC and BD. The endpoints efficacy, pain, aesthetics and patient preference are investigated during twelve months of follow up.

Superficial Basal Cell Carcinoma (sBCC) and Bowen Disease (BD) are malignant skin tumors localised in the superficial epidermis. These tumors are highly prevalent in the caucasian population. Diagnosis of sBCC and BD is often delayed because the clinical manifestation may be discrete and lesions are sometimes wrongly diagnosed and treated as eczema. Once the diagnosis is established, the lesions may cover an extensive area, making surgical excision more difficult. At that moment, the physician can make use of less invasive techniques such as photodynamic therapy (PDT). Pretreatment with an ablative carbon dioxide (CO2) laser has recently been studied in order to enhance the skin penetration of the photosensitizer methyl aminolevulinate (MAL). This study compares the results of a full ablative and a fractional ablative CO2 laser mode as pretreatment of PDT in the management of sBCC and BD. Ablation of the upper epiderm of the cancer results in an deeper penetration of MAL. Fractional ablation is known to result in better wound healing compared to full ablative CO2 laser ablation, because only small skin columns are ablated instead of the entire epidermal layer. Patients with non operable sBCC or BD lesions covering an area of at least 5 cm2 or with the presence of two small separated lesions, will be investigated. Lesions greater than 5 cm2 are divided in two. After randomization, the half of the lesions will be pretreated with the full ablative CO2 laser, while the other half with the fractional ablative CO2 laser. Afterwards, the entire surface is treated with MAL-PDT. Such as in our current clinical practice, this treatment modality is repeated after a two week interval. Thus, every subject undergoes both treatment modalities, making within-patient comparison possible. The endpoints efficacy, pain, aesthetics and patient preference are investigated during twelve months of follow up.

Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial

A Randomized Controlled Trial of a Full and a Fractional Ablative Carbon Dioxide Laser as Pretreatment for Photodynamic Therapy in the Management of Superficial Non Melanoma Skin Cancer

A three point scale with complete regression (CR), partial regression (PR) and no regression (NR) defined respectively as 100%, 25-99% and 0-25% regression.

The experienced pain during the treatment is scored bye the patient using a VAS scale of 100 mm.

The experienced pain during the treatment is scored by the patient using a VAS scale of 100 mm.

The presence of following side effects is evaluated by the investigator: erythema, vesicles, pigment changes, scarring, infection and pain.

The presence of following side effects is evaluated by the patient: erythema, vesicles, pigment changes, scarring, infection and pain.

The aesthetic result is scored by a blinded investigator using a four point scale: excellent (no significant changes), good (minor changes), poor (serious dyspigmentation, visible scarring), very poor (important scarring).

The aesthetic result is scored a by blinded investigator using a four point scale: excellent (no significant changes), good (minor changes), poor (serious dyspigmentation, visible scarring), very poor (important scarring).

The aesthetic result is scored by the patient using a four point scale: excellent (no significant changes), good (minor changes), poor (serious dyspigmentation, visible scarring), very poor (important scarring).

Patients are asked for their preferred therapy. Following options exist: (1) full ablative CO2 laser + PDT, (2) fractional ablative CO2 laser + PDT, (3) no preference

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
KTP vs CO2 Laser for the Treatment of Laryngeal Carcinoma	NCT02672904	Laryngeal Neopl...	CO2 laser KTP laser	18 Years -	Kaplan Medical Center
Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata	NCT06430190	Condylomata Acu...	Peginterferon α... Peginterferon α... CO2 laser	18 Years - 65 Years	First People's Hospital of Hangzhou
Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy	NCT04619485	Breast Cancer Genitourinary S...	CO2 LASER CO2 SHAM LASER	30 Years - 80 Years	Hospital Clinic of Barcelona
Post Excision/Mohs Scar Laser Resurfacing	NCT02130297	Skin Cancer	Laser Treatment	18 Years -	Icahn School of Medicine at Mount Sinai
Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata	NCT06430190	Condylomata Acu...	Peginterferon α... Peginterferon α... CO2 laser	18 Years - 65 Years	First People's Hospital of Hangzhou
Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial	NCT03012009	Bowen's Disease Superficial Bas...	full ablative C... fractional abla... MAL LED lamp lidocaine hydro...	18 Years -	University Hospital, Ghent

Spots Global Cancer Trial Database for co2 laser

Every month we try and update this database with for co2 laser cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for co2 laser

Every month we try and update this database with for co2 laser cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for co2 laser cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.